skip navigation

Scientific Days 2017

This landmark project is being lead by Laurence Zitvogel and Guido Kroemer.  Two full days of science based discussion regarding ImmunoOncology from the world leaders in their fields.  These “Principles of ImmunoOncology: A Practical Guide for Cancer Immunotherapy.” 

Registration

The Registration "Scientific Days 2017" is not currently available.

Target Audience

This activity is intended for physicians engaged in the care of patients with Cancer.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss novel practical knowledge of all aspects of administering immuno-oncology agent monotherapies to appropriate candidate patients.
  • Discuss novel practical knowledge of all aspects of combining a certain immunotherapy with various anti-cancer therapies, as well as with other types of immunotherapies (broadly defined as ‘CCIT’).
  • List the characteristics of optimal patient populations to be considered for clinical trials using candidate novel therapies: e.g., therapy allocation according to prognostic stage, line of therapy, sequencing of therapies, etc.
  • Apply novel methods for prognostication and prediction of therapeutic response to CIT/ CCIT using molecular and other putative biomarkers (for example, the use of immune stromal parameters captured in objective immunohistochemistry ‘read-out’ platforms –such as ImmunoScoreTM- and similar approaches).
  • Describe the current gaps in immunotherapy options and in which clinical scenarios could CCIT be best used with optimal benefit-risk (clinical safety) ratios.
  • Explain the optimal integration of CCIT novel approaches to achieve treatment goals, especially optimal toxicity identification and management.
  • Recognize the optimal pathways used by regulatory agencies for the expeditious performance of high-quality pivotal clinical trials that can credibly lead to timely CCIT approvals by regional health authorities (FDA, EMA, PMDA/MHLW, etc.) and eventual broad clinical use.
  • Discuss the direction of projects of translational science based on biological endpoints from analysis of tumor tissue from patients exposed to CIT/ CCIT approaches (correlative science/ exploratory endpoints in novel clinical trials).

Agenda

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and KC Consulting, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 11.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Fee Information

There is no fee for this educational activity.

Statement of Credit

A statement of credit will be issued immediately upon completing the evaluation on www.cmeuniversity.com.    (Paper copies if needed please email me@kcc-llc.com).

Faculty

Laurence Zitvogel, MD, PhD
Gustave Roussy Cancer Center, Villejuif, France
Guido Kroemer, MD, PhD
Gustave Roussy Cancer Center, Villejuif, France

Mathilde Allard, PhD,

University of Lausanne, Lausanne, Switzerland

 

Lionel Apetoh, PhD,

CGFL, University of Dijon, INSERM, Dijon, France

 

Paolo Ascierto, MD,

Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy

 

Cedrik Britten, MD,

GlaxoSmithKline, Stevenage, UK

 

Joshua Brody, MD,

Icahn School of Medicine at Mount Sinai, New York, USA

 

Christophe Caux, PhD,

Centre Léon Bérard, Lyon, France

 

Lisa Derosa, MD,

Gustave Roussy Cancer Center, Villejuif, France

 

Charles Drake, MD, PhD,

Herbert Irving Comprehensive Cancer Center, New York, USA

 

Glenn Dranoff, MD,

Novartis, Cambridge, USA

 

Alexander Eggermont, MD, PhD,

Gustave Roussy Cancer Center, Villejuif, France

 

Silvia Chiara Formenti, MD,

Weill Cornell Medicine, New York, USA

 

Wolf Herman Fridman, MD, PhD,

Centre de recherche des Cordeliers, Paris, France

 

Dmitry Gabrilovich, MD, PhD,

The Wistar Institute, Philadelphia, USA

 

David Ghez, MD,

Gustave Roussy Cancer Center, Villejuif, France

 

François Ghiringhelli, MD, PhD,

CGFL, University of Dijon, INSERM,, Dijon, France

 

Niels Halama, MD,

University of Heidelberg, Heidelberg, Germany

 

Roy Herbst, MD,

Yale University, New Haven, USA

 

Andrew Kaiser, PhD,

Miltenyi Biotec, Bergisch Gladbach, Germany

 

Guido Kroemer, MD, PhD,

Gustave Roussy Cancer Center, Villejuif, France

 

Yohann Loriot, MD,

Gustave Roussy Cancer Center, Villejuif, France

 

Markus Maeurer, MD, PhD,

Karolinska Institutet, Stockholm, Sweden

 

Aurélien Marabelle, MD, PhD,

Gustave Roussy Cancer Center, Villejuif, France

 

Ignacio Melero, MD, PhD,

CIMA and Clinica Universidad de Navarra, Pamplona, Spain

 

Cornelis Melief, MD, PhD,

University of Leiden, Leiden, Holland

 

Ira Mellman, MD,

Genentech, South San Francisco, USA

 

Michael Platten, MD, PhD,

German Cancer Research Center (DKFZ), Heidelberg, Germany

 

George Prendergast, MD, PhD,

Lankenau Institute for Medical Research (LIMR), Philadelphia, USA

 

Igor Puzanov, MD,

Roswell Park Cancer Institute, Buffalo, USA

 

John Reed, MD, PhD,

Roche, Basel, Switzerland

 

Emmanuela Romano, MD, PhD,

Institut Curie, Paris, France

 

Pedro Romero, MD,

Université de Lausanne, Lausanne, Switzerland

 

Bertrand Routy, MD,

Gustave Roussy Cancer Center, Villejuif, France

 

Nicholas Sarlies, MD, PhD,

Sellas Life Sciences Group, New York, USA

 

Catherine Sautès-Fridman, MD, PhD,

Centre de recherche des Cordeliers, Paris, France

 

Dirk Schadendorf, MD,

University of Essen, Essen, Germany

 

Mark Smyth, PhD,

QIMR Berghofer Medical Research Institute, Brisbane, Australia

 

Jean-Charles Soria, MD, PhD,

Gustave Roussy Cancer Center, Villejuif, France

 

Daniel Speiser, PhD,

University of Lausanne, Lausanne, Switzerland

 

Tadatsugu Taniguchi, PhD,

University of Tokyo, Tokyo, Japan

 

Eric Tartour, MD, PhD,

Höpital Européen Georges Pompidou, Paris, France

 

Janis Taube, MD, PhD,

Johns Hopkins University School of Medicine, Baltimore, USA

 

Michèle Teng, PhD,

QIMR Berghofer Medical Research Institute, Brisbane, Australia

 

Cornelia Trimble, MD, PhD,

Johns Hopkins University School of Medicine, Baltimore, USA

 

Dario Vignali, PhD,

University of Pittsburgh, Pittsburgh, USA

 

Eric Vivier, Vet, PhD,

Centre d'Immunologie de Marseille-Luminy, Marseille, France

 

Jennifer Wargo, MD, PhD,

University of Texas - MD Anderson Cancer Center, Houston, USA

 

Laurence Zitvogel, MD, PhD,

Gustave Roussy Cancer Center, Villejuif, France

 

Weiping Zou, MD, PhD,

University of Michigan School of Medicine, Ann Arbor, USA

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Americans with Disabilities Act

éEvent staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact KC Consulting prior to the live event at 011.973.610.9630.

Jointly provided by Post Graduate Institute for Medicine and KC Consulting

Supporters

This activity is supported by an independent educational grant from Miltenyl Biotec SAS, Incyte Corporation, Servier, Lytix Biopharma AS, and the European Academy of Tumor Immunology.